

Contents

Preface *xvii*

Part I General Aspects 1

| | | |
|----------|---|----------|
| 1 | New Trends in Drug Discovery | 3 |
| | <i>Gerd Schnorrenberg</i> | |
| 1.1 | Introduction | 3 |
| 1.1.1 | Analysis of New Molecular Entities Approved in 2015 | 3 |
| 1.2 | New Trends in NCE Discovery | 7 |
| 1.3 | Enhanced Lead Generation Strategies | 7 |
| 1.3.1 | Analogue Approach | 9 |
| 1.3.2 | High Throughput Screening (HTS) | 9 |
| 1.3.3 | Structure-Based Design | 11 |
| 1.3.4 | Virtual Screening | 12 |
| 1.3.5 | Fragment-Based Lead Discovery | 13 |
| 1.3.6 | Repositioning | 14 |
| 1.3.7 | Additional New Trends in Hit/Lead Generation | 15 |
| 1.4 | Early Assessment of Development Aspects during Drug Discovery | 16 |
| 1.4.1 | DMPK | 17 |
| 1.4.2 | Assessment of Physicochemical Parameters | 18 |
| 1.4.3 | Tolerability Assessment | 19 |
| 1.5 | New Biological Entities (NBEs) | 19 |
| 1.5.1 | Antibody Engineering to Reduce Immunogenicity | 23 |
| 1.5.2 | Progress in Antibody Production and Engineering of Physicochemical Properties | 24 |
| 1.5.3 | Engineering to Improve Efficacy | 25 |
| 1.5.4 | New Formats | 26 |
| 1.5.4.1 | Antibody–Drug Conjugates | 26 |
| 1.5.4.2 | Bispecific Antibodies | 28 |
| 1.6 | General Challenges in Drug Discovery | 30 |
| 1.7 | Summary | 31 |
| | Acknowledgments | 31 |
| | List of Abbreviations | 31 |
| | References | 32 |

| | | |
|----------|---|-----------|
| 2 | Patenting Small and Large Pharmaceutical Molecules | 41 |
| | <i>Uwe Albersmeyer, Ralf Malessa, and Ulrich Storz</i> | |
| 2.1 | The Role of Patents in the Pharmaceutical Industry | 41 |
| 2.2 | Classification of Active Pharmaceutical Ingredient Grouping | 42 |
| 2.3 | Patentability Criteria and Patentable Embodiments | 43 |
| 2.3.1 | Patent Eligibility and Patentability | 43 |
| 2.3.2 | Patent Eligibility of Molecules | 43 |
| 2.3.2.1 | Small Molecules and Peptides | 44 |
| 2.3.2.2 | Molecules Isolated from Nature | 44 |
| 2.3.3 | Novelty | 44 |
| 2.3.3.1 | Novelty of Molecules that are More or Less Identical to Molecules from the Human Body | 46 |
| 2.3.4 | Inventive Step/Non-Obviousness | 47 |
| 2.3.5 | Patentability Criteria and Patentable Embodiments in Biopharmaceutics | 47 |
| 2.3.5.1 | Different Types of Biopharmaceutics | 47 |
| 2.3.5.2 | Monoclonal Antibodies | 48 |
| 2.3.5.3 | Nucleic Acid-Based Therapeutics | 49 |
| 2.4 | Patent Term Extensions and Adjustments, Supplementary Protection Certificates, and Data Exclusivity in Biopharmaceutics | 49 |
| 2.4.1 | Introduction | 49 |
| 2.4.2 | Patent Lifetime | 49 |
| 2.4.2.1 | Patent Term Adjustment (PTA) | 50 |
| 2.4.2.2 | Patent Term Extension (PTE) and Supplementary Protection Certificates (SPC) | 50 |
| 2.4.2.3 | Pediatric Investigations (EU) | 52 |
| 2.4.3 | Exclusivity Privileges Related to Regulatory Procedures | 53 |
| 2.4.3.1 | Data Exclusivity and Market Exclusivity | 53 |
| 2.4.3.2 | Orphan Drugs | 54 |
| 2.5 | Patent Lifecycle Management | 57 |
| 2.5.1 | Formulations and/or Galenics | 57 |
| 2.5.2 | Combination Products | 57 |
| 2.5.3 | Second or Higher Medical Indication | 58 |
| 2.5.4 | New Dosage Regimens | 59 |
| 2.5.5 | Further Options for Small Molecules | 59 |
| 2.5.6 | Divisional Applications | 60 |
| 2.6 | Conclusion | 60 |
| | List of Abbreviations | 60 |
| | References | 61 |
| | Part II Drug Class Studies | 65 |
| 3 | Kinase Inhibitor Drugs | 67 |
| | <i>Peng Wu and Amit Choudhary</i> | |
| 3.1 | Introduction | 67 |
| 3.2 | Historical Overview | 70 |

| | | |
|----------------------------------|---|------------|
| 3.2.1 | Before 1980 | 70 |
| 3.2.2 | 1980s | 70 |
| 3.2.3 | 1990s | 70 |
| 3.2.4 | After 2000 | 72 |
| 3.3 | Approved Kinase Inhibitors | 72 |
| 3.3.1 | FDA-Approved Non-Covalent Small-Molecule Kinase Inhibitors | 74 |
| 3.3.1.1 | Bcr–Abl Inhibitors | 74 |
| 3.3.1.2 | ErbB Family Inhibitors | 77 |
| 3.3.1.3 | VEGFR Family Inhibitors | 77 |
| 3.3.1.4 | JAK Family Inhibitors | 78 |
| 3.3.1.5 | ALK Inhibitors | 78 |
| 3.3.1.6 | MET Inhibitors | 78 |
| 3.3.1.7 | B-Raf Inhibitors | 79 |
| 3.3.1.8 | MEK Inhibitors | 79 |
| 3.3.1.9 | PI3K Inhibitor | 79 |
| 3.3.1.10 | CDK Inhibitor | 80 |
| 3.3.2 | FDA Approved Covalent Small Molecule Kinase Inhibitors | 80 |
| 3.3.3 | FDA-Approved Rapalogs | 80 |
| 3.3.4 | Other Approved Kinase Inhibitors | 81 |
| 3.4 | New Directions | 82 |
| 3.5 | Conclusion | 83 |
| | List of Abbreviations | 83 |
| | References | 83 |
| 4 | Evolution of Nonsteroidal Androgen Receptor Antagonists | 95 |
| | <i>Arwed Cleve and Duy Nguyen</i> | |
| 4.1 | Introduction | 95 |
| 4.2 | Flutamide (Eulexin [®]) | 96 |
| 4.3 | Nilutamide (Anandron [®]) | 98 |
| 4.4 | Bicalutamide (Casodex [®]) | 99 |
| 4.5 | Enzalutamide (Xtandi [®]) | 102 |
| 4.6 | Outlook | 106 |
| 4.7 | Conclusion | 106 |
| | List of Abbreviations | 106 |
| | References | 107 |
| | | |
| Part III Case Studies 111 | | |
| 5 | Development of T-Cell-Engaging Bispecific Antibody Blinatumomab (Blinicyto[®]) for Treatment of B-Cell Malignancies | 113 |
| | <i>Patrick A. Baeuerle</i> | |
| 5.1 | Introduction | 113 |
| 5.1.1 | Brief History of Bispecific Antibodies | 114 |
| 5.1.2 | History of T-Cell-Engaging Antibodies | 115 |

| | | |
|----------|--|------------|
| 5.1.3 | History and Design of Blinatumomab | 116 |
| 5.1.4 | Blinatumomab Mode of Action | 117 |
| 5.1.5 | Manufacturing of Blinatumomab | 118 |
| 5.1.6 | Clinical Development of Blinatumomab | 118 |
| 5.1.7 | Administration of Blinatumomab | 120 |
| 5.1.8 | Side Effects of Blinatumomab | 121 |
| 5.2 | Discussion | 122 |
| 5.2.1 | Other BiTE™ Antibodies in Development | 124 |
| 5.2.2 | Blinatumomab versus CD19 CAR-T Cell Therapy | 125 |
| 5.3 | Summary | 126 |
| | List of Abbreviations | 126 |
| | References | 127 |
| 6 | Ceritinib: A Potent ALK Inhibitor for the Treatment of Crizotinib-Resistant Non-Small Cell Lung Cancer Tumors | 131 |
| | <i>Pierre-Yves Michellys</i> | |
| 6.1 | Introduction | 131 |
| 6.2 | Drug Design and Strategy | 134 |
| 6.3 | Synthesis of Ceritinib | 135 |
| 6.4 | <i>In Vitro</i> Evaluation of Ceritinib | 136 |
| 6.5 | <i>In Vitro</i> ADME Evaluation of Ceritinib | 137 |
| 6.6 | Preclinical Pharmacokinetic Evaluation of Ceritinib | 138 |
| 6.7 | <i>In Vivo</i> Evaluation of Ceritinib | 138 |
| 6.8 | Evaluation of Ceritinib in Crizotinib-Resistance Mutations | 140 |
| 6.9 | Mouse Model of Crizotinib-Resistant Tumors | 141 |
| 6.10 | Clinical Phase I Evaluation of Ceritinib | 143 |
| 6.11 | Conclusion | 146 |
| | List of Abbreviations | 146 |
| | References | 146 |
| 7 | Discovery, Development, and Mechanisms of Action of the Human CD38 Antibody Daratumumab | 153 |
| | <i>Maarten L. Janmaat, Niels W.C.J. van de Donk, Jeroen Lammerts van Bueren, Tahamtan Ahmadi, A. Kate Sasser, Richard K. Jansson, Henk M. Lokhorst, and Paul W.H.I. Parren</i> | |
| 7.1 | Introduction | 153 |
| 7.2 | CD38: The Target | 154 |
| 7.2.1 | CD38 as a Therapeutic Target | 154 |
| 7.2.2 | CD38 Function | 154 |
| 7.2.3 | CD38 Expression in Normal Tissue | 155 |
| 7.2.4 | CD38 Expression in Cancer | 155 |
| 7.3 | Discovery of Daratumumab | 156 |
| 7.4 | Daratumumab Combines Multiple Mechanism of Actions | 157 |
| 7.4.1 | Complement-Dependent Cytotoxicity (CDC) | 157 |
| 7.4.2 | Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) | 158 |
| 7.4.3 | Antibody-Dependent Cellular Phagocytosis (ADCP) | 158 |
| 7.4.4 | Programmed Cell Death (PCD) | 159 |

| | | |
|----------|--|------------|
| 7.4.5 | Enzymatic Modulation | 159 |
| 7.4.6 | Immunomodulation | 160 |
| 7.5 | Single-Agent Antitumor Activity of Daratumumab in Multiple Myeloma | 160 |
| 7.5.1 | Monotherapy Studies with Daratumumab | 163 |
| 7.5.2 | Factors That Predict Response to Daratumumab | 164 |
| 7.5.3 | Daratumumab in Other Plasma Cell Dyscrasias | 164 |
| 7.5.4 | Subcutaneous Delivery of Daratumumab | 165 |
| 7.5.5 | Interference of Daratumumab in Clinical Laboratory Assays | 165 |
| 7.6 | Daratumumab-Based Combination Therapies in Multiple Myeloma | 166 |
| 7.6.1 | Preclinical Combination Studies | 167 |
| 7.6.2 | Clinical Combination Studies | 168 |
| 7.7 | Potential of Daratumumab Outside Multiple Myeloma | 171 |
| 7.7.1 | Other Hematologic Malignancies | 171 |
| 7.7.2 | Solid Tumors | 171 |
| 7.7.3 | Autoimmune Disorders | 172 |
| 7.8 | Conclusions and Future Perspectives | 173 |
| 7.9 | Summary | 175 |
| | List of Abbreviations | 176 |
| | References | 178 |
| 8 | The Discovery of Obeticholic Acid (Ocaliva™): First-in-Class FXR Agonist | 197 |
| | <i>Roberto Pellicciari, Mark Pruzanski, and Antimo Gioiello</i> | |
| 8.1 | Introduction | 197 |
| 8.2 | Bile Acids in Health and Disease | 197 |
| 8.2.1 | Structure and Properties of Natural Bile Acids | 197 |
| 8.2.2 | Physiology | 200 |
| 8.2.3 | Bile Acids as Therapeutic Agents | 202 |
| 8.3 | The Early Bile Acid Medicinal Chemistry Program at the University of Perugia | 204 |
| 8.4 | The Breakthrough (1999): Bile Acids Are the Endogenous Ligands of the Farnesoid X Receptor (FXR) | 210 |
| 8.5 | Discovery of 6 α -Ethyl-Chenodeoxycholic Acid (6-ECDCA, INT-747, Obeticholic Acid) | 214 |
| 8.5.1 | Design, Synthesis, and Structure–Activity Relationships of C6-Modified CDCA Derivatives | 214 |
| 8.5.2 | Scale-Up Synthesis of Obeticholic Acid | 220 |
| 8.6 | Properties and Preclinical Studies of Obeticholic Acid | 222 |
| 8.6.1 | Physicochemical Properties, Pharmacokinetics, and Metabolism | 222 |
| 8.6.2 | OCA in Preclinical Models of Liver Diseases | 225 |
| 8.7 | Obeticholic Acid (Ocaliva™) for the Treatment of Primary Biliary Cholangitis (PBC): Phases I–III Clinical Studies to Establish Clinical Efficacy | 228 |
| 8.8 | Conclusions and Future Directions | 230 |
| | List of Abbreviations | 231 |
| | References | 232 |

- 9** **Discovery and Development of Obinutuzumab (GAZYVA, GAZYVARO), a Glycoengineered Type II Anti-CD20 Antibody for the Treatment of Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia** 245
Christian Klein, Ekkehard Mössner, Marina Bacac, Günter Fingerle-Rowson, and Pablo Umaña
- 9.1 Introduction 245
- 9.2 Preclinical Experience with Obinutuzumab 246
- 9.2.1 Characteristics and Mechanisms of Action of Type I and Type II CD20 Antibodies 246
- 9.2.2 Obinutuzumab Development, Chemistry, and Production 247
- 9.2.3 CD20 Binding by Obinutuzumab 248
- 9.2.4 Complement-Dependent Cytotoxicity 249
- 9.2.5 Direct Cell Death Induction 249
- 9.2.6 FcγR Binding 249
- 9.2.7 Antibody-Dependent Cellular Cytotoxicity and Antibody-Dependent Cellular Phagocytosis 250
- 9.2.8 Whole Blood B-Cell Depletion 250
- 9.2.9 Activity of Single-Agent Obinutuzumab in Human Xenograft Models of B-Cell Lymphoma 251
- 9.2.10 Activity of Obinutuzumab Combined with Chemotherapy and Novel Agents in Human Xenograft Models of B-Cell Lymphoma 251
- 9.2.11 Conclusions from Preclinical Studies 252
- 9.3 Clinical Experience with Obinutuzumab 253
- 9.3.1 Non-Hodgkin Lymphoma 253
- 9.3.1.1 Early Clinical Experience (Phase I/II) 253
- 9.3.1.2 Phase III Studies 262
- 9.3.1.3 Ongoing Clinical Studies of Novel Combinations, Including Chemotherapy-Free Regimens 269
- 9.3.2 Chronic Lymphocytic Leukemia 270
- 9.3.2.1 Early Clinical Experience (Phase I/II) 270
- 9.3.2.2 Phase III Studies 272
- 9.3.2.3 Ongoing Clinical Studies of Novel Combinations, Including Chemotherapy-Free Regimens 273
- 9.3.3 Obinutuzumab in Non-tumor Indications 273
- 9.4 Conclusions 274
- Acknowledgments 274
- List of Abbreviations 275
- References 276
- 10** **Omarigliptin (MARIZEV™, MK-3102)** 291
Tesfaye Biftu
- 10.1 Introduction 291
- 10.1.1 Discovery of Omarigliptin 293
- 10.1.2 X-ray and Modeling Studies 297

| | | |
|----------|--|-----|
| 10.1.3 | Synthesis of Omarigliptin | 298 |
| 10.1.4 | <i>In Vitro</i> Pharmacology | 302 |
| 10.1.4.1 | <i>In Vivo</i> Pharmacology in Preclinical Species | 302 |
| 10.1.4.2 | Pharmacokinetics (PK) in Preclinical Species | 303 |
| 10.1.4.3 | Pharmaceutical Properties | 304 |
| 10.1.4.4 | Preclinical Safety Pharmacology | 304 |
| 10.1.4.5 | Clinical Data | 305 |
| 10.1.5 | Add-On Studies | 308 |
| 10.1.5.1 | Add-On to Metformin and Sitagliptin | 308 |
| 10.1.5.2 | Add-On to Glimepiride | 310 |
| 10.1.5.3 | Safety and Tolerability | 311 |
| 10.2 | Summary | 311 |
| | List of Abbreviations | 312 |
| | References | 313 |
| | | |
| 11 | Opicapone, a Novel Catechol-O-Methyltransferase Inhibitor (COMT) to Manage the Symptoms of Parkinson's Disease | 319 |
| | <i>László E. Kiss, Maria João Bonifácio, José Francisco Rocha, and Patrício Soares-da-Silva</i> | |
| 11.1 | Introduction | 319 |
| 11.2 | COMT Inhibitors Used in L-DOPA Treatment | 320 |
| 11.3 | The Discovery of Opicapone | 322 |
| 11.3.1 | Early Pyrazole Analogues | 322 |
| 11.3.2 | Modulation of the Central Heterocyclic Core | 325 |
| 11.3.3 | Optimization of Oxadiazolyl Nitrocatechols | 327 |
| 11.3.4 | Identification of Opicapone | 330 |
| 11.4 | Opicapone Preclinical Profile | 332 |
| 11.5 | Clinical Studies with Opicapone | 333 |
| 11.5.1 | Phase I and Phase II Studies | 333 |
| 11.5.2 | Phase III Studies | 334 |
| 11.6 | Conclusion | 335 |
| | List of Abbreviations | 336 |
| | References | 336 |
| | | |
| 12 | The Discovery of Osimertinib (TAGRISSO™): An Irreversible Inhibitor of Activating and T790M Resistant Forms of the Epidermal Growth Factor Receptor Tyrosine Kinase for the Treatment of Non-Small Cell Lung Cancer | 341 |
| | <i>Michael J. Waring</i> | |
| 12.1 | Introduction | 341 |
| 12.2 | Discussion | 346 |
| 12.3 | Summary | 353 |
| | List of Abbreviations | 354 |
| | Acknowledgment | 355 |
| | References | 355 |

- 13 Discovery of Pitolisant, the First Marketed Histamine H₃-Receptor Inverse Agonist/Antagonist for Treating Narcolepsy 359**
C. Robin Ganellin, Jean-Charles Schwartz, and Holger Stark
- 13.1 Introduction 359
- 13.2 Chemical Background 360
- 13.3 Generation of a Chemical Lead 362
- 13.4 Pharmacological Screening Methods 366
- 13.5 Structure–Activity Optimization 367
- 13.6 Generation of Pitolisant 369
- 13.7 Preclinical Development Studies 371
- 13.8 Clinical Development Studies 373
- 13.9 Conclusion 374
- Acknowledgment 375
- List of Abbreviations 375
- References 375
-
- 14 Discovery and Development of Safinamide, a New Drug for the Treatment of Parkinson’s Disease 383**
Paolo Pevarello and Mario Varasi
- 14.1 Introduction 383
- 14.1.1 Parkinson’s Disease 383
- 14.1.2 From James Parkinson to L-Dopa 385
- 14.1.3 Pharmacotherapy of Parkinson’s Disease 386
- 14.2 Discovery of Safinamide 387
- 14.2.1 From Milacemide to Safinamide 388
- 14.2.2 SAR Efforts on 2-Aminoamide Analogues Provide Lead Molecules 391
- 14.2.3 *In Vivo* Antiepileptic Efficacy Assessment Identifies Safinamide 395
- 14.3 Mechanisms of Action of Safinamide 396
- 14.3.1 Safinamide Inhibits MAO-B 396
- 14.3.2 Safinamide Blocks Voltage-Dependent Sodium Channels (VDSCs) 398
- 14.3.3 Safinamide Modulates Voltage-Dependent Calcium Channels (VDCCs) 399
- 14.3.4 Safinamide Inhibits Glutamate Release 399
- 14.4 Preclinical *In Vivo* Pharmacological Characterization of Safinamide 399
- 14.4.1 Preclinical Epilepsy Models 400
- 14.4.2 Preclinical PD Models 401
- 14.5 Pharmacokinetics and Metabolism (PKM) 402
- 14.5.1 Preclinical PKM 402
- 14.5.2 Clinical PKM and Safety 403
- 14.6 Clinical Efficacy of Safinamide 403
- 14.6.1 Clinical Studies in Early PD 403
- 14.6.2 Clinical Studies in Advanced PD 406
- 14.6.3 Clinical Trials for Other Indications 407

| | | |
|-----------|--|------------|
| 14.7 | Safety and Tolerability in Clinical Studies | 408 |
| 14.8 | Summary of Clinical Trials and Marketing Authorization | 408 |
| 14.9 | Conclusion | 408 |
| | List of Abbreviations | 409 |
| | References | 410 |
| 15 | Discovery and Development of Trifluridine/Tipiracil (Lonsurf™) | 417 |
| | <i>Norihiko Suzuki, Masanobu Ito, and Teiji Takechi</i> | |
| 15.1 | Introduction | 417 |
| 15.2 | A Concept to Maximize the Antitumor Effect of 5-FU | 419 |
| 15.3 | A Concept to Maximize the Antitumor Effect of FTD | 420 |
| 15.3.1 | Medicinal Chemistry: <i>In Vitro</i> and Pharmacokinetic Studies | 420 |
| 15.3.2 | Preclinical <i>In vivo</i> Efficacy Studies | 425 |
| 15.4 | The Mechanism Underlying the Antitumor Effect of Trifluridine | 427 |
| 15.5 | Characterization of the Pharmacologic Effect of FTD/TPI | 429 |
| 15.6 | Clinical Pharmacology and Determination of the Optimal Dosing Scheme of FTD/TPI | 430 |
| 15.7 | Clinical Efficacy, Safety, and Approval | 432 |
| 15.8 | Summary | 434 |
| | List of Abbreviations | 435 |
| | References | 435 |
| | Index | 443 |

